Able Labs Recall Of All Marketed Products Boosts 2005 Drug Recall Total
Executive Summary
Generic drug manufacturer Able Laboratories' recall of all of its marketed products following an FDA GMP inspection accounted for half of the substantial rise of products recalled during 2005 versus the previous year
You may also be interested in...
FDA Cites Able For Failing To Reject Out-Of-Specification Drugs, Altering Data
Able Labs routinely failed to reject drugs that did not meet established standards, specifications and quality control criteria, according to FDA inspectional observations included in a "Form 483" report
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: